ReviewTherapeutic advances in reproductive health
Mitochondrial enrichment in infertile patients: a review of different mitochondrial replacement therapies.
Review in Therapeutic advances in reproductive health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Autologous bone marrow mesenchymal stem cell mitochondrial transplantation in recurrent assisted reproductive technology failure: a randomized controlled trial.Stem cell research & therapy · 2026Trial
- Current state of the art in the transmission of mitochondrial DNA pathogenic variants: reviewing preventive-therapeutic alternatives.Journal of assisted reproduction and genetics · 2026Review
- Mitochondrial DNA Modification in Assisted Reproduction: Concept to Practice-A Narrative Review.International journal of molecular sciences · 2026Review
- Engineered mitochondria in diseases: mechanisms, strategies, and applications.Signal transduction and targeted therapy · 2025Review
- From Bench to Bedside: Translating Cellular Rejuvenation Therapies into Clinical Applications.Cells · 2024Review
- Novel Advances in Cell-Free Therapy for Premature Ovarian Failure (POF): A Comprehensive Review.Advanced pharmaceutical bulletin · 2024Review
- Targeting mitochondria for ovarian aging: new insights into mechanisms and therapeutic potential.Frontiers in endocrinology · 2024Review
- Mitochondrial DNA copy number variation and gene mutations mediate polycystic ovary syndrome: research progress.American journal of translational research · 2024Review
- Ovarian aging: mechanisms and intervention strategies.Medical review (2021) · 2022Review
- CRISPR Technology: A Jewish Legal Perspective.Rambam Maimonides medical journal · 2022Article
- Review
- In vivo and in vitro postovulatory aging: when time works against oocyte quality?Journal of assisted reproduction and genetics · 2022Review
- Enucleated oocyte donation: first for infertility treatment, then for mitochondrial diseases.Journal of assisted reproduction and genetics · 2022Article
- Review
- Treatment modalities for poor ovarian responders.Therapeutic advances in reproductive healthArticle
- EnhancingGynecology and minimally invasive therapyArticle
- Improvement of oocyte quality through the SIRT signaling pathway.Reproductive medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor ovarian responders exhibit a quantitative reduction in their follicular pool, and most cases are also associated with poor oocyte quality due to patient's age, which leads to impaired
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.